12/2
07:07 pm
fgen
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit [Yahoo! Finance]
Low
Report
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit [Yahoo! Finance]
12/2
04:05 pm
fgen
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
Low
Report
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
11/11
12:30 am
fgen
FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ... [Yahoo! Finance]
High
Report
FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ... [Yahoo! Finance]
11/10
10:02 pm
fgen
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/10
04:32 pm
fgen
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/10
04:02 pm
fgen
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
11/3
04:02 pm
fgen
FibroGen to Report Third Quarter 2025 Financial Results
Low
Report
FibroGen to Report Third Quarter 2025 Financial Results
10/7
07:36 am
fgen
Progentos Therapeutics Names Paul Frohna Chief Medical Officer [Yahoo! Finance]
Medium
Report
Progentos Therapeutics Names Paul Frohna Chief Medical Officer [Yahoo! Finance]
9/24
10:34 am
fgen
FibroGen (NASDAQ:FGEN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
Low
Report
FibroGen (NASDAQ:FGEN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
9/24
07:26 am
fgen
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]
Low
Report
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]
9/24
07:00 am
fgen
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
Low
Report
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer